Vyas, P., Récher, C., Döhner, H., Venditti, A., Salek, S., Nier, S., Boluda, B., Requena, G. A., Prince-Eladnani, R., Borlenghi, E., Curti, A., Theunissen, K., Puyuelo, A., Rus, I. C., Leeuw, D. D., Ammatuna, E., Saini, L., Maertens, J., Schuh, A., Camanho, D., Sullivan, A., Bigne, A. D. L., Romagnoli, M., Cognet, B., DiNardo, C., Vives, S. (2025). ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC). Blood. https://doi.org/10.1182/blood-2025-3443